Literature DB >> 23196257

A subset of CD8+ T cells acquiring selective suppressive properties may play a role in GvHD management.

Irit Avivi1, Dina Stroopinsky, Jacob M Rowe, Tamar Katz.   

Abstract

Difficulty in segregating graft-versus-tumor effect (GvT) from graft-versus-host disease (GvHD) remains a major limitation of allogeneic stem cell transplantation (Allo SCT). Naturally occurring regulatory T cells have been suggested to suppress alloreactive T cells involved in GvHD; however, their non-selective suppressive effect raises concern regarding probable attenuation of the GvT effect. Recent studies suggested inducible CD8 (iCD8) cells to be useful in suppressing autoimmune reactions, although their function in the Allo SCT setting has not been fully explored. The current study assessed in-vitro the properties of iCD8 T cells, generated in response to allogeneic dendritic cells (DCs), imitating the Allo SCT conditions. CD25(-) peripheral blood mononuclear cells (PBMCs) were stimulated with allogeneic DCs in mixed lymphocyte culture (MLC). The resultant iCD8(+)CD25(+) population was isolated and assessed for phenotypic markers, cytokine expression profile, cell proliferation, inhibitory capacity and anti-viral response. The generated CD8(+)CD25(+)FOXP3(+) T cells selectively inhibited the primary allogeneic response, without attenuating T cell response against other stimuli, such as mitogens or a cytomegalovirus (CMV) recall antigen. In conclusion, iCD8(+)CD25(+) cells suppress allogeneic stimulation, while maintaining the capacity to respond to infectious pathogens. These cells could be potentially efficient in the Allo SCT setting, where GvHD prevention is required.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23196257     DOI: 10.1016/j.trim.2012.11.006

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  7 in total

1.  Memory CD4+ T cells are suppressed by CD8+ regulatory T cells in vitro and in vivo.

Authors:  Xin Long; Qi Cheng; Huifang Liang; Jianping Zhao; Jian Wang; Wei Wang; Stephen Tomlinson; Lin Chen; Carl Atkinson; Bixiang Zhang; Xiaoping Chen; Peng Zhu
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

Review 2.  Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells.

Authors:  Simona Ronchetti; Erika Ricci; Maria Grazia Petrillo; Luigi Cari; Graziella Migliorati; Giuseppe Nocentini; Carlo Riccardi
Journal:  J Immunol Res       Date:  2015-04-15       Impact factor: 4.818

3.  Immunosuppressive effects of multipotent mesenchymal stromal cells on graft-versus-host disease in rats following allogeneic bone marrow transplantation.

Authors:  Oral Nevruz; Ferit Avcu; A Uğur Ural; Aysel Pekel; Bahar Dirican; Mükerrem Safalı; Elvin Akdağ; Murat Beyzadeoğlu; Tayfun Ide; Ali Sengül
Journal:  Turk J Haematol       Date:  2013-09-05       Impact factor: 1.831

Review 4.  Description of CD8+ Regulatory T Lymphocytes and Their Specific Intervention in Graft-versus-Host and Infectious Diseases, Autoimmunity, and Cancer.

Authors:  Martha R Vieyra-Lobato; Jorge Vela-Ojeda; Laura Montiel-Cervantes; Rubén López-Santiago; Martha C Moreno-Lafont
Journal:  J Immunol Res       Date:  2018-08-05       Impact factor: 4.818

Review 5.  Future prospects for CD8+ regulatory T cells in immune tolerance.

Authors:  Léa Flippe; Séverine Bézie; Ignacio Anegon; Carole Guillonneau
Journal:  Immunol Rev       Date:  2019-10-08       Impact factor: 12.988

Review 6.  Harnessing CD8+CD28- Regulatory T Cells as a Tool to Treat Autoimmune Disease.

Authors:  Sabrina Ceeraz; Charlotte R Thompson; Richard Beatson; Ernest H Choy
Journal:  Cells       Date:  2021-11-01       Impact factor: 6.600

Review 7.  Newly Found Peacekeeper: Potential of CD8+ Tregs for Graft-Versus-Host Disease.

Authors:  Weihao Wang; Tao Hong; Xiaoqi Wang; Rui Wang; Yuxuan Du; Qiangguo Gao; Shijie Yang; Xi Zhang
Journal:  Front Immunol       Date:  2021-11-24       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.